Targeting long-term success in pharma's largest and fastest-growing space, with Bayer's Robert LaCaze

2 March 2017

“A focused strategy but one that’s diverse within the areas of focus that we have” sums up the approach of Bayer (BAYN: DE) and Robert LaCaze in oncology as they sets their sights on making a big difference in this highly competitive and rapidly evolving environment.

Mr LaCaze is executive vice president of the German pharma major’s new Oncology Strategic Business Unit (SBU), launched only last month.

Of course, Bayer is one of countless companies seeking to take a lead role in the fight against cancer, with barely a day going by without news reflecting the explosion of immuno-oncology assets, the potential of genomic medicines or other developments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK